Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
NCT03965091 · Teva Branded Pharmaceutical Products R&D, Inc. · PHASE2 · terminated · last registry update 2023-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Met pre-specified criteria for futility at interim analysis” | – | Registry record, Teva Branded Pharmaceutical Products R&D, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-02Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04041284)
- 2023-09-29Also stopped (terminated): Diamond Headache Clinic, Galcanezumab (NCT05492695)
- 2023-06-09Phase 3 first posted: H. Lundbeck A/S, Eptinezumab + Placebo (NCT05897320)
- 2022-08-19Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT03963232)
- 2022-07-22Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04418765)
- 2022-07-14Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT05458011)
- 2022-04-13Results posted on the registry: David True, Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY] (NCT04461795)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision